Avid Bioservices Inc (CDMO)

[Protector]

PPHM CEO King's idea explained by Dr Wolchok (MSKCC)

CEO King said after the annual (I think it is the one of 3 or 4 years ago) that he would be interested to see a combination of Cotara and Bavituxiab.

He, nor anybody else, ever explained what the interest in that would be. But that changes now. Dr. Wolchok, in the video below, elaborates on the combo's in IO including chemo and radiation and actually explains it at the conceptual level. As a consequence one can see this is comparable to King's idea of several years ago. (BTW in case of doubt I posted at the time that he said that on the annual so the exact time can be found back: Keywords King Annual Cotara).

video min 22+

He actually explains what I have explained several times before and which Dr. Brekken has ALSO said some more then a year ago but I forgot where that was. It are TWO things.

Chemo en Radio BOTH create cell damage debris, from healthy as well as from cancer cells, only chemo does it in a body wide way (poor targeting) while radio does it on a path through the tumor which is more targeted.

Dr. Brekken, and now Dr. Wolchok emphasised the NEED for that debris because it is based on what is in there that the immune system reacts and can learn (see explanation index 22min in video).

BUT it is also well known that the immune system undergoes other influence from signalling (PD-1, CTLA-4, PS, ...). That is where IO comes in.

Radio seems to be, again see Wolchok, the prefered way to go. But Dr. Wolchok speaks about traditional radio therapy, the one that still impacts a path of healthy cells due to the fact that the beam cannot be concentrated on the tumor only.

Cotara is a radio therapy that does exactly that. It delivers the radio-active substance inside the tumor and radiates from there, but can be dosed in such a way that the collateral damage of healthy cells outside that area is limited. Hence the concentration of debris of tumour cells is MUCH higher compare to the healthy ones as it is in traditional radio therapy.

SO imagine a clinical trial for SOLID CANCERS where in stead of a full operation and after treatment with chemo or radio, one makes a small cut and creates a path through which the Cotara Dual Catheter can be inserted to drip 25H. Much less invasive then full blow operations. Then a anti-PD-1/anti-CTLA-4/anti-PS (Bavituximab) IO treatment is given (maybe starting a few days upfront with bavituximab) and the two others after the infusion when the immune system starts to more quickly reproduce T-cells.

I wonder if there are people at PPHM thinking around these solutions.